Research & Education

Radiation Webinar - Advances in Radiation Therapy

Friday, September 25, 2015 - 6 p.m. JST / 11 a.m. CEST - Recording Available

The IASLC Education Committee is pleased to announce the second program in the 2015 series of Live Webinars presented by the Advanced Radiation Technology Committee. This subcommittee is focused on providing educational and informational programs addressing state of the art radiation therapy for lung cancer. This live program will be moderated by Francoise Mornex, MD, PhD and feature presentations by Yong Chan Ahn, MD, PhD and Yasushi Nagata, M.D., Ph.D.

Françoise MORNEX Yong Chan Ahn Yasushi Nagata 

Program Chair
PR Françoise Mornex , MD, PhD

Département de Radiothérapie
Centre Hospitalier Lyon Sud
LYON, France

Yong Chan Ahn, MD, PhD

Professor
Dept. of Radiation Oncology
Samsung Medical Center
Sungkyunkwan University School of Medicine

Yasushi Nagata, M.D., Ph.D.

Professor and Chairman,
Department of Radiation Oncology,
Hiroshima University,
Graduate School of Biomedical Science,
Hiroshima, Japan

Name of Reviewer(s): 

              

Fred Hirsch, MD, PhD –Speaker/Advisory Board: AstraZeneca, Genentech, BMS, Lilly,Abbvie.

Name of Planner(s): 

 

    Deb Whippen-Nothing to Disclose

Name of Activity: 

 

Advances in Radiation Therapy

Date of Activity:

 

09/25/2015

Faculty/Speaker(s):

Financial DISCLOSURES

 

PR Françoise Mornex , MD, PhD-Moderator-Consulting for: Lilly, Roche and Boehringrt-Ingelheim

Yong Chan Ahn, MD, PhD- Speaker- Nothing to Disclose

Yasushi Nagata, M.D., Ph.D.- Speaker- Nothing to Disclose

Type of Activity: 

 Live Course

  Internet Live Course (Webinar)

 Internet Enduring Material

Are there Commercial Supporters for this activity?

       Yes    

If yes, please list: Supported by an unrestricted grant from Elekta

SBRT for Early-Stage Non-Small Cell Lung Cancer - Yasushi Nagata, M.D., Ph.D.

Stereotactic body radiotherapy (SBRT) is a new technique, introduced in the late 1990s. SBRT is a method of using single 10-20Gy of high dose and hypofractionated radiotherapy. Recently, many papers have been published on its clinical results, especially in stage I lung cancer. The indications, updated clinical trials and future strategy of SBRT will be discussed.

After attending this session attendees will be able to:

  1. Illustrade the indications of SBRT for early-stage NSCLC
  2. Review the updated clinical trials of SBRT for early-stage NSCLC.
  3. Discuss the future strategy of SBRT for early-stage NSCLC.

Management of Oligometastatic Cancer - Presented by Yong Chan Ahn, MD, PhD

With the improvements both in the oncologic diagnostics and therapeutics, the proportion of lung cancer patients who develop oligometastasis has recently been on increasing trend. Management of lung cancer patients with oligometastasis has naturally emerged as a challenging issue. Concept of oligometastasis and its management strategy will be discussed.

After attending this session, attendees will be able to:

  1. Illustrade and identify subgroup of patients who might be benefited by aggressive local treatment modality.
  2. Determine radiation therapy strategy, including stereotactic ablative irradiation, to achieve reasonable local control at minimum toxicity level.

Following the presentations there will be ample opportunity for the audience to submit questions and comments to the faculty via Internet chat.

DOWNLOAD RECORDING

CME Information:

Financial/Commercial Relationships DISCLOSURES

 

A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used, on patients that benefits the individual in any financial amount and therefore, may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. 

 This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME assures that the planners/reviewers/authors/faculty/moderators/peer reviewers et. al. conflicts of interest  were identified, reviewed and resolved from all individuals involved in the development  or able to influence and control the content of this CME activity; IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners.  Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from any of IASLC CME activity presentation.

 

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Subcommittee, and Independent reviewer. COI will be evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

 

CREDIT STATEMENT

 

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

 

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

GOAL & PURPOSE

 

Stereotactic body radiotherapy (SBRT) is a new technique, introduced in the late 1990s. SBRT is a method of using single 10-20Gy of high dose and hypofractionated radiotherapy. Recently, many papers have been published on its clinical results, especially in stage I lung cancer. The indications, updated clinical trials and future strategy of SBRT will be discussed.

 

TARGET AUDIENCE

 

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

 

DISCLAMER

 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Thank you for your participation.

 

 

 IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)

Participants who complete a pre-and post-test along with an evaluation will receive 1 AMA PRA Category 1 CreditTM for each completed webinar.  

If you are interested in obtaining the CME Credits for these sessions you must indicate this when you register for the program. CME Credit is only available for those that participate in the Live Session.

This live webinar series is designed to meet the educational needs of radiation oncologists, medical oncologists, thoracic surgeons, radiologists, pathologists, and advanced practice nurses, physician's assistants and other healthcare professionals who diagnose and treat patients with lung cancer.

Location Local time Time zone UTC offset
New York (U.S.A. - New York) Friday, September 25, 2015 at 5:00:00 AM EDT UTC-4 hours
Paris (France) Friday, September 25, 2015 at 11:00:00 AM CEST UTC+2 hours
London (United Kingdom - England) Friday, September 25, 2015 at 10:00:00 AM BST UTC+1 hour
Madrid (Spain) Friday, September 25, 2015 at 11:00:00 AM CEST UTC+2 hours
Tokyo (Japan) Friday, September 25, 2015 at 6:00:00 PM JST UTC+9 hours
Bangkok (Thailand) Friday, September 25, 2015 at 4:00:00 PM ICT UTC+7 hours
Kuala Lumpur (Malaysia) Friday, September 25, 2015 at 5:00:00 PM MYT UTC+8 hours
Beijing (China) Friday, September 25, 2015 at 5:00:00 PM CST UTC+8 hours
Hong Kong (Hong Kong) Friday, September 25, 2015 at 5:00:00 PM HKT UTC+8 hours
Taipei (Taiwan) Friday, September 25, 2015 at 5:00:00 PM CST UTC+8 hours
Corresponding UTC (GMT) Friday, September 25, 2015 at 09:00:00 AM    

How to use the Time Zone Converter